Targets › TGFB2
4 programs from 3 companies in 28 trials: 13 Phase 2, 7 Phase 3, 7 Phase 1, 1 Phase 4; Oncology, Hematology, Ophthalmology; next expected readout Dec 2026.
[Transforming growth factor beta-2 proprotein]: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively..; FUNCTION: [Latency-associated peptide]: Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix (By…. (UniProt, P61812)
Open in Phaseline: the race on TGFB2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Luspatercept (ACE-536) Transforming growth factor beta inhibitor | TGFB1, TGFB2, TGFB3 | Phase 4 | Anemia; Myelodysplastic Syndromes; Beta-thalassemia; CCUS Clonal Cytopenia of Undetermined Significance … | Jul 2027 |
| Bristol-Myers Squibb | Luspatercept (ACE-536) Transforming growth factor beta inhibitor | TGFB1, TGFB2, TGFB3 | Phase 3 | Myelodysplastic Syndromes; Myelodysplastic Syndromes (MDS); Myeloproliferative Disorders; Beta-Thalassemia | Sep 2027 |
| National Cancer Institute (NCI) | Bintrafusp Alfa (M7824) Programmed cell death 1 ligand 1 binding agent; Transforming growth factor beta binding agent | CD274, TGFB1, TGFB2, TGFB3 | Phase 2 | Thymic Epithelial Tumor; Cancer Of Prostate; Kaposi Sarcoma; Urothelial Cancer | Dec 2026 |
| Oncotelic | Trabedersen (OT-101) Transforming growth factor beta-2 mRNA antisense inhibitor | TGFB2 | Phase 2 | Pancreatic Ductal Adenocarcinoma; Myopia, Progressive; Non-small Cell Lung Cancer | Jun 2027 |
Myelodysplastic Syndromes (8) Anemia (3) Pancreatic Ductal Adenocarcinoma (1) Myopia, Progressive (1) Non-small Cell Lung Cancer (1) Thymic Epithelial Tumor (1) Cancer Of Prostate (1) Kaposi Sarcoma (1) Urothelial Cancer (1) Beta-thalassemia (1) CCUS Clonal Cytopenia of Undetermined Significance (1) Transfusion-dependent β-thalassemia Patients (1)
small molecule (2), antibody (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.